Firms, funds, people, portfolio companies and transactions from sworn filings and cited announcements, kept as a graph with a date and a source on every edge. Reported gross assets are never fund size, regulatory AUM is never dry powder, and a deal value prints only when someone disclosed it.

The names on this page are hidden. Create a free account and they fill in. No card, and every figure, date and source on this page is public either way.

Transactions / P••••••• R•••

W•••••• P•••••-Led Investor Group Agrees to Acquire Controlling Interest in P•••••••® R•••

Exit to a strategic buyerannouncedannounced Jul 13, 2026Fact
What happened
Target
P••••••• R•••
Platform
not an add-on on record
Control
unknown
Share acquired
unknown
Industry
healthcare / health care, pharma
Target location
unknown
Seller kind
Sponsor
Rollover
unknown
Values, only where disclosed
Enterprise value
Not disclosed
Purchase price
Not disclosed
Equity value
Not disclosed
Target revenue
Not disclosed
Target EBITDA
Not disclosed
Multiple
Not disclosed
Parties and roles
10 named
Buy side
  • W•••••• P••••• L••Strategic acquirerconfirmed
    “W•••••• P•••••, the pioneer of global growth investing, today announced that a W•••••• P•••••-led investor group has agreed to acquire a controlling interest in P••••••• R•••, the leading independent rare pharmacy in the United States, from N••••• Partners, General Atlantic, and The Vistria Group.”
Sell side
  • N••••• P•••••••• L••Sellerconfirmed
    “About N••••• Partners N••••• P•••••••• L•• is a middle-market private equity firm based in Providence, Rhode Island, that focuses on investments in three sectors: healthcare, industrials, and services.”
Advisory side
  • J••• M••••• S••••••••• L••Buy-side adviserconfirmed
    “J••• M••••• S••••••••• L•• served as financial advisor to W•••••• P•••••.”
  • R•••• • G••• L••Legal adviserconfirmed
    “R•••• & G••• served as legal counsel to P•••••••.”
  • C••••• G•••••••Legal adviserconfirmed
    “C••••• G••••••• served as legal counsel to W•••••• P•••••.”
  • C••••••••• P••••••• L••Sell-side adviserconfirmed
    “C••••••••• Partners and G•••••• S•••• • C•• L•• served as financial advisors to P•••••••.”
  • G•••••• S•••• • C•• L••Sell-side adviserconfirmed
    “C••••••••• Partners and G•••••• S•••• • C•• L•• served as financial advisors to P•••••••.”
Side not stated
  • A••• K•••••••Managementconfirmed
    “We look forward to partnering with B•••• and the P••••••• team to support the Company's continued growth and expand access to life-changing therapies for patients with rare diseases across the United States," added A••• K•••••••, Managing Director, W•••••• P•••••.”
  • B•••• N••••Managementconfirmed
    “We are grateful for the partnership and support from N••••• Partners, General Atlantic, and The Vistria Group, whose investment helped expand our impact for patients and shape the company we are today," said B•••• N••••, Chief Executive Officer of P•••••••.”
  • P••••••• R•••Targetconfirmed
    “W•••••• P•••••, the pioneer of global growth investing, today announced that a W•••••• P•••••-led investor group has agreed to acquire a controlling interest in P••••••• R•••, the leading independent rare pharmacy in the United States, from N••••• Partners, General Atlantic, and The Vistria Group.”
Evidence
“W•••••• P•••••, the pioneer of global growth investing, today announced that a W•••••• P•••••-led investor group has agreed to acquire a controlling interest in P••••••• R•••, the leading independent rare pharmacy in the United States, from N••••• Partners, General Atlantic, and The Vistria Group.”
Press release wires (PR Newswire, GlobeNewswire, Business Wire public pages and RSS)confidence 80%recorded Sep 14, 2026
W•••••• P•••••-Led Investor Group Agrees to Acquire Controlling Interest in P•••••••® R••• | Private Equity Intelligence | DFX